Clinical Trial Update: PUFA Augmentation in Treatment of Major Depression [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating polyunsaturated fatty acid (PUFA) augmentation for major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Polyunsaturated fatty acids (PUFA)

Snippet

Sponsor: National Center for Complementary and Integrative Health (NCCIH) | Conditions: Major Depression | Phase 3 | Status: COMPLETED